Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
Coronado Initiates Phase I Clinical Trial of Rationally Designed Fourth Generation Doxorubicin Analogue
January 15th, 2008
Coronado Biosciences Inc. announced that the first patient has been treated in a Phase I clinical trial of CNDO101, a rationally designed fourth generation doxorubicin analogue. The uniquely designed Phase I dose-escalation study in adult patients with advanced cancer will investigate the safety and preliminary efficacy of CNDO101 (5-imino-13 deoxy-doxorubicin). The trial has eight dose levels and allows patients to move to higher doses with each cycle if there is no evidence of toxicity. This modified design should allow the investigators to demonstrate evidence of anti-cancer activity. Coronado expects to enroll at least 30 patients in this study. ...
Source: Cancer Weekly (2008-01-15)
|
